Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Stakeholders

2. Research & Forecasting

• 2.1. Research Methodology
  • 2.1.1. Research Instruments
    • 2.1.1.1. Secondary Instrument
    • 2.1.1.2. Primary Instrument
  • 2.1.2. Research Approaches
    • 2.1.2.1. Bottom-up Approach
    • 2.1.2.2. Top-down Approach
  • 2.1.3. Research Reliability & Validity
  • 2.1.4. Research Assumptions
  • 2.1.5. Vendor Inclusion Criteria
• 2.2. Forecasting Methodology
  • 2.2.1. Methodology for Market Estimation & Forecasting
  • 2.2.2. Significance and Importance of the Market Estimation & Forecasting

3. Executive Summary

4. Premium Insight

• 4.1. Market Connectivity
• 4.2. Market Data Feed
• 4.3. Market Vendor Ranking Analysis
• 4.4. Market Dynamics
  • 4.4.1. Drivers
    • 4.4.1.1. Growing incidences of cancer
    • 4.4.1.2. Adoption of immunotherapy over other treatment options
    • 4.4.1.3. Development of bioinformatic tools enhancing the drug development process
    • 4.4.1.4. Rise in healthcare expenditure and healthcare insurance
    • 4.4.1.5. Technological advancement and R&D for the treatment of cancer
  • 4.4.2. Restraints
    • 4.4.2.1. High cost associated with the treatment
  • 4.4.3. Opportunities
    • 4.4.3.1. Clinical trials to cure different cancers in immunotherapy
    • 4.4.3.2. Moving toward personalized immunotherapy
    • 4.4.3.3. Combination of modern immunotherapy and traditional medicines increasing survival rate
  • 4.4.4. Challenges
    • 4.4.4.1. Cancer limiting the immune response
• 4.5. Porter’s Five Forces Analysis
  • 4.5.1. Threat of New Entrants
  • 4.5.2. Threat of Substitutes
  • 4.5.3. Bargaining Power of Customers
  • 4.5.4. Bargaining Power of Suppliers
  • 4.5.5. Industry Rivalry

5. Global Cancer Immunotherapy Market, by Function

• 5.1. Introduction
• 5.2. Breast Cancer
• 5.3. Colorectal Cancer
• 5.4. Head & Neck Cancer
• 5.5. Lung Cancer
• 5.6. Melanoma
• 5.7. Multiple Myeloma
• 5.8. Prostate Cancer

6. Global Cancer Immunotherapy Market, by Product

• 6.1. Introduction
• 6.2. Cell Therapies
  • 6.2.1. Chimeric Antigen Receptor T Cell Therapy
  • 6.2.2. Dendritic Cells
• 6.3. Checkpoint Inhibitors
  • 6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
  • 6.3.2. Programmed Death 1 & Programmed Death Ligand 1
• 6.4. Immunomodulators
  • 6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
  • 6.4.2. Interferons
  • 6.4.3. Interleukins
  • 6.4.4. Oncolytic Virus
• 6.5. Monoclonal Antibodies
  • 6.5.1. Bispecific Monoclonal Antibodies
  • 6.5.2. Conjugated Monoclonal Antibodies
  • 6.5.3. Naked Monoclonal Antibodies
• 6.6. Vaccines
  • 6.6.1. Prophylactic Vaccines
  • 6.6.2. Therapeutic Vaccines

7. Global Cancer Immunotherapy Market, by End User

• 7.1. Introduction
• 7.2. Cancer Research Institutes
• 7.3. Clinics
• 7.4. Hospitals

8. Global Cancer Immunotherapy Market, by Geography

• 8.1. Introduction
• 8.2. Americas Cancer Immunotherapy Market
  • 8.2.1. Americas Cancer Immunotherapy Market, by Country
    • 8.2.1.1. United States
    • 8.2.1.2. Brazil
    • 8.2.1.3. Canada
    • 8.2.1.4. Mexico
    • 8.2.1.5. Argentina
  • 8.2.2. Americas Cancer Immunotherapy Market, by Function
  • 8.2.3. Americas Cancer Immunotherapy Market, by Product
  • 8.2.4. Americas Cancer Immunotherapy Market, by End User
• 8.3. Europe, Middle East & Africa Cancer Immunotherapy Market
  • 8.3.1. Europe, Middle East & Africa Cancer Immunotherapy Market, by Country
    • 8.3.1.1. United Kingdom
    • 8.3.1.2. Germany
    • 8.3.1.3. France
    • 8.3.1.4. Saudi Arabia
    • 8.3.1.5. United Arab Emirates
    • 8.3.1.6. Italy
    • 8.3.1.7. Russia
  • 8.3.2. Europe, Middle East & Africa Cancer Immunotherapy Market, by Function
  • 8.3.3. Europe, Middle East & Africa Cancer Immunotherapy Market, by Product
  • 8.3.4. Europe, Middle East & Africa Cancer Immunotherapy Market, by End User
• 8.4. Asia-Pacific Cancer Immunotherapy Market
  • 8.4.1. Asia-Pacific Cancer Immunotherapy Market, by Country
    • 8.4.1.1. China
    • 8.4.1.2. Japan
    • 8.4.1.3. India
    • 8.4.1.4. Australia
  • 8.4.2. Asia-Pacific Cancer Immunotherapy Market, by Function
  • 8.4.3. Asia-Pacific Cancer Immunotherapy Market, by Product
  • 8.4.4. Asia-Pacific Cancer Immunotherapy Market, by End User

9. Competitive Strategic Window

• 9.1. Introduction
  • 9.1.1. Leverage Zone
  • 9.1.2. Vantage Zone
  • 9.1.3. Speculative Zone
  • 9.1.4. Bottleneck Zone

10. FPNV Positioning Matrix

• 10.1. Introduction
• 10.2. Scores
  • 10.2.1. Forefront
  • 10.2.2. Pathfinders
  • 10.2.3. Niche
  • 10.2.4. Vital
• 10.3. Business Strategy
• 10.4. Product Satisfaction

11. Competitive News Feed Analysis

12. Company Usability Profiles

• 12.1. Amgen Inc.
• 12.2. Astrazeneca
• 12.3. Bayer AG
• 12.4. Bristol-Myers Squibb
• 12.5. Celgene Corporation
• 12.6. ELI Lilly and Company
• 12.7. F. Hoffmann-La Roche Ltd
• 12.8. GlaxoSmithKline Plc
• 12.9. Janssen Global Services, LLC
• 12.10. Merck
• 12.11. Novartis
• 12.12. Pfizer
• 12.13. Seattle Genetics, Inc.
• 12.14. Spectrum Pharmaceuticals, Inc.

13. Appendix

• 13.1. Top Reports
• 13.2. Author Details

LIST OF TABLES (39 TABLES)

TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET RANKING, BY VENDORS, 2017

TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)

TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)

TABLE 22. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 23. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)

TABLE 24. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 25. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 26. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 27. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)

TABLE 28. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 29. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 30. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)

TABLE 31. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)

TABLE 32. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)

TABLE 33. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)

TABLE 34. 360IRESEARCH SCORES FOR FOREFRONT IN CANCER IMMUNOTHERAPY MARKET

TABLE 35. 360IRESEARCH SCORES FOR PATHFINDERS IN CANCER IMMUNOTHERAPY MARKET

TABLE 36. 360IRESEARCH SCORES FOR NICHE IN CANCER IMMUNOTHERAPY MARKET

TABLE 37. 360IRESEARCH SCORES FOR VITAL IN CANCER IMMUNOTHERAPY MARKET

TABLE 38. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR CANCER IMMUNOTHERAPY MARKET

TABLE 39. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR CANCER IMMUNOTHERAPY MARKET

LIST OF FIGURES (35 TABLES)

FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET: YEARS CONSIDERED FOR THE STUDY

FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH METHODOLOGY

FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH INSTRUMENTS

FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY SECONDARY INSTRUMENT SOURCES

FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY POTENTIAL RESPONDENTS

FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT

FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH APPROACHES

FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY DATA TRIANGULATION

FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH ASSUMPTIONS

FIGURE 10. CANCER IMMUNOTHERAPY MARKET: KEY MARKET CONNECTIVITY

FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)

FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)

FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)

FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)

FIGURE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)

FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017 (USD MILLION)

FIGURE 31. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FUNCTION, 2024

FIGURE 32. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT, 2024

FIGURE 33. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2024

FIGURE 34. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY GEOGRAPHY, 2024

FIGURE 35. 360IRESEARCH FPNV POSITIONING MATRIX FOR CANCER IMMUNOTHERAPY MARKET

The global cancer immunotherapy market is expected to grow from USD 76,523.68 million 2017 to USD 220,315.85 million by the end of 2024 at a Compound Annual Growth Rate (CAGR) of 16.31%.

“Growing incidences of cancer
is one of the factors largely attributing to the growth of cancer immunotherapy market globally”

The factors attributing to the growth of the market are growing incidences of cancer, adoption of immunotherapy over other treatment options, development of bioinformatic tools enhancing the drug development process, rise in healthcare expenditure and healthcare insurance, and technological advancement and r&d for the treatment of cancer. However, some factors such as and high cost associated with the treatment may hinder the market growth. The global cancer immunotherapy market is expected to showcase the opportunities such as clinical trials to cure different cancers in immunotherapy, moving toward personalized immunotherapy, and combination of modern immunotherapy and traditional medicines increasing survival rate. In the near future, the market may face the possible challenges in the growth due to and cancer limiting the immune response. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the global cancer immunotherapy market market.“Breast Cancer: The highest growing function for the global cancer immunotherapy market”

On the basis of function, the global cancer immunotherapy market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. Among all these function, the Breast Cancer is projected to hold the largest market share while the Lung Cancer has the potential to grow the market with the highest CAGR in the forecast period.“Monoclonal Antibodies: The highest growing product for the global cancer immunotherapy market”

On the basis of product, the global cancer immunotherapy market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. Among all these product, the Monoclonal Antibodies is projected to hold the largest market share while the Checkpoint Inhibitors has the potential to grow the market with the highest CAGR in the forecast period.“Hospitals: The highest growing end user for the global cancer immunotherapy market”

On the basis of end user, the global cancer immunotherapy market is studied across Cancer Research Institutes, Clinics, and Hospitals. Among all these end user, the Hospitals has captured the maximum market share while the Cancer Research Institutes has the opportunity to emerge with the highest CAGR.“Americas: The highest growing geography for the global cancer immunotherapy market”

On the basis of geography, the global cancer immunotherapy market is studied across Americas, (United States, Brazil, Canada, Mexico, and Argentina) Europe, Middle East & Africa, (United Kingdom, Germany, France, Saudi Arabia, United Arab Emirates, Italy, and Russia) and Asia-Pacific (China, Japan, India, and Australia). Among all these geography, the Europe, Middle East & Africa is showing the maximum growth in the near future with the highest CAGR while the Americas is dominating the market with highest market size.

“Amgen Inc.: The potential growing player for the global cancer immunotherapy market”

The key players profiled in the global cancer immunotherapy market are Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Janssen Global Services, LLC, Merck, Novartis, Pfizer, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the global cancer immunotherapy market.
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the global cancer immunotherapy market.
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the global cancer immunotherapy market.
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the global cancer immunotherapy market.
5. Competitive Assessment & Intelligence: Provides exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global cancer immunotherapy market.